TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 11441903

Group type: EXPERIMENTAL
Intervention: Hydrocortisone 40 microg/kg/h
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Hydrocortisone 300 microg/kg/h
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Hydrocortisone 600 microg/kg/h
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: All hydrocortisone groups
Number of subjects: 40
Study: 9881885

Group type: EXPERIMENTAL
Intervention: L. casei Shirota-fermented milk (100 ml three times daily for 4 weeks)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (unfermented milk, 100 ml three times daily for 4 weeks)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: L. casei Shirota-fermented milk
Number of subjects: 20
Study: 7626438

Group type: EXPERIMENTAL
Intervention: Dedicated Short Stay Spinal Surgical Unit
Number of subjects: 85
Study: 2507181

Group type: EXPERIMENTAL
Intervention: Nalbuphine (200 micrograms.kg‐1 bolus + 50 micrograms.kg‐1.hr‐1 infusion)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nalbuphine (other dosages: 100 micrograms.kg‐1 + 25 micrograms.kg‐1.hr‐1 and 50 micrograms.kg‐1 + 12.5 micrograms.kg‐1.hr‐1)
Number of subjects: 0
Study: 309931

Group type: EXPERIMENTAL
Intervention: Aspirin
Number of subjects: 43

Group type: COMPARATOR
Intervention: Acetaminophen
Number of subjects: 43
Study: 31771038

Group type: EXPERIMENTAL
Intervention: Arthroscopic microfracture technique in combination with autologous bone marrow stem cells transplantation
Number of subjects: 46
Study: 30953483

Group type: EXPERIMENTAL
Intervention: Family-based intervention via WeChat
Number of subjects: 222

Group type: COMPARATOR
Intervention: Usual care (Control)
Number of subjects: 222
Study: 28715712

Group type: EXPERIMENTAL
Intervention: Anodal tDCS at 1mA
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Anodal tDCS at 2mA
Number of subjects: 33

Group type: COMPARATOR
Intervention: Sham tDCS
Number of subjects: 33
Study: 26010884

Group type: EXPERIMENTAL
Intervention: Sequential treatment strategy using FOLFIRI.3 and gemcitabine (Arm 2)
Number of subjects: 98

Group type: COMPARATOR
Intervention: Gemcitabine alone (Arm 1)
Number of subjects: 98
Study: 23670358

Group type: EXPERIMENTAL
Intervention: COLD drinks (4°C)
Number of subjects: 8

Group type: COMPARATOR
Intervention: WARM drinks (28°C)
Number of subjects: 8
Study: 21633948

Group type: EXPERIMENTAL
Intervention: Endovenous laser ablation (EVLA)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Cryostripping
Number of subjects: 120
Study: 19303015

Group type: EXPERIMENTAL
Intervention: Angiotensin II
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Captopril (ACE inhibitor)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sulphasalazine (IKK inhibitor)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Losartan (AT1 antagonist)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 17409897

Group type: EXPERIMENTAL
Intervention: Women with advanced NSCLC
Number of subjects: 1157

Group type: COMPARATOR
Intervention: Men with advanced NSCLC
Number of subjects: 1157
Study: 15243278

Group type: EXPERIMENTAL
Intervention: Once-weekly alendronate (ALN) 70 mg
Number of subjects: 456

Group type: COMPARATOR
Intervention: Raloxifene (RLX) 60 mg daily
Number of subjects: 456
Study: 11061584

Group type: EXPERIMENTAL
Intervention: Paroxetine 20 mg/d for 2 weeks
Number of subjects: 20
Study: 9029461

Group type: EXPERIMENTAL
Intervention: Porcelain/Vitapan teeth
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Ivoclar Orthosit
Number of subjects: 70

Group type: COMPARATOR
Intervention: Other denture teeth (Premierdent, Acrotone, Rx1, Duravite)
Number of subjects: 70
Study: 8287341

Group type: EXPERIMENTAL
Intervention: Triple therapy with a bismuth compound, metronidazole and either amoxicillin or tetracycline
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Anti-H. pylori therapy added to conventional ulcer treatment
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study: 2457074

Group type: EXPERIMENTAL
Intervention: Hydromorphone 4 mg
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Hydromorphone 8 mg
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Naloxone 0.1 mg
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Naloxone 0.2 mg
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Butorphanol 0.375 mg
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Butorphanol 0.75 mg
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Butorphanol 1.5 mg
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Butorphanol 3 mg
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Butorphanol 6 mg
Number of subjects: 5

Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 5
Study: 30869991

Group type: EXPERIMENTAL
Intervention: Acupressure
Number of subjects: 118

Group type: COMPARATOR
Intervention: Sham Acupressure
Number of subjects: 118

Group type: COMPARATOR
Intervention: Control
Number of subjects: 118

Group type: COMPARATOR
Intervention: Acupressure and Sham Acupressure
Number of subjects: 118
Study: 31228287

Group type: EXPERIMENTAL
Intervention: Parametric method when Shapiro-Wilk P > 0.2
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Nonparametric method
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Box-Cox transformation parametric method
Number of subjects: 120
Study: 28536999

Group type: EXPERIMENTAL
Intervention: OBV/PTV/r + RBV for 16 weeks
Number of subjects: 171

Group type: EXPERIMENTAL
Intervention: OBV/PTV/r + RBV for 12 weeks
Number of subjects: 171

Group type: EXPERIMENTAL
Intervention: OBV/PTV/r + RBV for 16 weeks (treatment-experienced)
Number of subjects: 171

Group type: EXPERIMENTAL
Intervention: OBV/PTV/r + RBV for 16 weeks (treatment-experienced, relapsed after interferon therapy)
Number of subjects: 171

Group type: EXPERIMENTAL
Intervention: OBV/PTV/r + RBV for 16 weeks (HCV GT2a infection)
Number of subjects: 171

Group type: EXPERIMENTAL
Intervention: OBV/PTV/r + RBV for 16 weeks (HCV GT2b infection)
Number of subjects: 171

Group type: EXPERIMENTAL
Intervention: OBV/PTV/r + RBV for 12 weeks (HCV GT2a infection)
Number of subjects: 171

Group type: EXPERIMENTAL
Intervention: OBV/PTV/r + RBV for 12 weeks (HCV GT2b infection)
Number of subjects: 171
Study: 25680390

Group type: EXPERIMENTAL
Intervention: STeleR intervention
Number of subjects: 52

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 52
Study: 22605788

Group type: EXPERIMENTAL
Intervention: Benchmarking feedback
Number of subjects: 3980

Group type: COMPARATOR
Intervention: Non-benchmarked feedback
Number of subjects: 3980
Study: 21724265

Group type: EXPERIMENTAL
Intervention: Sertraline (50mg/day p.o.)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study: 19758440

Group type: EXPERIMENTAL
Intervention: HR+/HER2+ tumors
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: HR-/HER2- tumors
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Ki67 labeling index
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Biology-based tumor type
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: HR+/HER2- tumors
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: HR-/HER2+ tumors
Number of subjects: 116
Study: 16769215

Group type: EXPERIMENTAL
Intervention: Patellofemoral joint replacement (PFJR)
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Unrevised knees without preoperative trochlear dysplasia
Number of subjects: 103

Group type: COMPARATOR
Intervention: Unrevised knees with preoperative trochlear dysplasia
Number of subjects: 103
Study: 15259324

Group type: EXPERIMENTAL
Intervention: First target (T1) presented at fixation, second target (T2) varied in location and timing.
Number of subjects: 1
Study: 11128665

Group type: EXPERIMENTAL
Intervention: Paroxetine (20-40 mg daily)
Number of subjects: 191

Group type: COMPARATOR
Intervention: Amitriptyline (75-150 mg daily)
Number of subjects: 191

Group type: EXPERIMENTAL
Intervention: Paroxetine
Number of subjects: 191

Group type: COMPARATOR
Intervention: Amitriptyline
Number of subjects: 191
Study: 9048712

Group type: EXPERIMENTAL
Intervention: [123I]FP-CIT SPECT in patients with early Parkinson's disease
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: [123I]FP-CIT SPECT in patients with advanced Parkinson's disease
Number of subjects: 18

Group type: COMPARATOR
Intervention: Control group (age matched healthy volunteers)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: [123I]FP-CIT SPECT in Parkinson's disease patients
Number of subjects: 18
Study: 8038023

Group type: EXPERIMENTAL
Intervention: Ultrafiltration
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 24
Study: 2869745

Group type: EXPERIMENTAL
Intervention: N-propylnorapomorphine (19 mg oral dose)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: N-propylnorapomorphine (subchronic dosage schedule)
Number of subjects: 0
Study: 31805549

Group type: EXPERIMENTAL
Intervention: Topical Dorzolamide for one week
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Hypercapnic gas mixture breathing
Number of subjects: 0
Study: 29858000

Group type: EXPERIMENTAL
Intervention: GP MDI 28.8 μg
Number of subjects: 248

Group type: EXPERIMENTAL
Intervention: GP MDI 14.4 μg
Number of subjects: 248

Group type: EXPERIMENTAL
Intervention: GP MDI 7.2 μg
Number of subjects: 248

Group type: EXPERIMENTAL
Intervention: GP MDI 3.6 μg
Number of subjects: 248

Group type: EXPERIMENTAL
Intervention: GP MDI 1.9 μg
Number of subjects: 248

Group type: COMPARATOR
Intervention: Placebo MDI
Number of subjects: 248

Group type: EXPERIMENTAL
Intervention: SAL DPI 50 μg
Number of subjects: 248
Study: 27608921

Group type: EXPERIMENTAL
Intervention: Lunch ad libitum
Number of subjects: 154

Group type: COMPARATOR
Intervention: No lunch
Number of subjects: 154
Study: 24530156

Group type: EXPERIMENTAL
Intervention: Intact ovaries
Number of subjects: 222

Group type: COMPARATOR
Intervention: Prior oophorectomy
Number of subjects: 222
Study: 23539002

Group type: EXPERIMENTAL
Intervention: Customized Unna boot
Number of subjects: 32

Group type: COMPARATOR
Intervention: Simple bandage application
Number of subjects: 32
Study: 21234625

Group type: EXPERIMENTAL
Intervention: Targeted school-based drama group therapy (DGT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Teaching maths and English
Number of subjects: 0
Study: 18497346

Group type: EXPERIMENTAL
Intervention: 200 mg oral mifepristone
Number of subjects: 180

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 180
Study: 17066611

Group type: EXPERIMENTAL
Intervention: Radiofrequency ablation and mucosal plication (RAMP)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Ligature and excision procedure (LEP)
Number of subjects: 46
Study: 12594112

Group type: EXPERIMENTAL
Intervention: Extracorporeal shock wave therapy (ESWT)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Regular treatment (group 1)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Simulated treatment (group 2)
Number of subjects: 70
Study: 11020616

Group type: EXPERIMENTAL
Intervention: Automated Corneal Shaper (ACS) microkeratome
Number of subjects: 137

Group type: COMPARATOR
Intervention: Hansatome microkeratome
Number of subjects: 137
Study: 9028062

Group type: EXPERIMENTAL
Intervention: Artificial pneumothorax
Number of subjects: 57

Group type: COMPARATOR
Intervention: Standard treatment with antituberculous drugs and corticosteroids
Number of subjects: 57
Study: 2064144

Group type: EXPERIMENTAL
Intervention: Methacholine (MTH) challenge
Number of subjects: 16
Study: 6293264

Group type: EXPERIMENTAL
Intervention: Cyclic treatment with chlorambucil, methotrexate and 5‐fluorouracil
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cyclophosphamide, methotrexate and 5‐fluorouracil
Number of subjects: 0
Study: 31608552

Group type: EXPERIMENTAL
Intervention: Semaglutide 0.5 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Semaglutide 1.0 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Semaglutide
Number of subjects: 0
Study: 31574794

Group type: EXPERIMENTAL
Intervention: Heyan Kuntai Capsule (HYKT)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 27345931

Group type: EXPERIMENTAL
Intervention: Inhaled levodopa formulation (CVT-301)
Number of subjects: 86

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 86
Study: 24995515

Group type: EXPERIMENTAL
Intervention: Albinterferon (various doses/regimens)
Number of subjects: 141

Group type: COMPARATOR
Intervention: Pegylated‐interferon‐α2a
Number of subjects: 141
Study: 23523026

Group type: EXPERIMENTAL
Intervention: Ultrasound-assisted extraction of phenolic compounds using 1g plant sample with 12 mL of 35% ethanol for 40 min.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ultrasound-assisted extraction of phenolic compounds
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Selected extract from ultrasound-assisted extraction
Number of subjects: 0
Study: 21078951

Group type: EXPERIMENTAL
Intervention: BMS‐488043 800 mg
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: BMS‐488043 1,800 mg
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: BMS‐488043
Number of subjects: 30
Study: 19588284

Group type: COMPARATOR
Intervention: Lidocaine spray (S)
Number of subjects: 1864

Group type: EXPERIMENTAL
Intervention: Viscous lidocaine (V)
Number of subjects: 1864
Study: 16723058

Group type: EXPERIMENTAL
Intervention: Nicorandil 0.1 mg kg‐1 (Group N)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Normal saline (Group P)
Number of subjects: 47
Study: 15078044

Group type: EXPERIMENTAL
Intervention: Active navigation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Passive learning
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Map learning
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Navigating in a real environment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Navigating through a virtual simulation
Number of subjects: 0
Study: 11921832

Group type: EXPERIMENTAL
Intervention: Filter Paper Haemagglutination Inhibition (FPHAI)
Number of subjects: 165

Group type: COMPARATOR
Intervention: Serum Haemagglutination Inhibition (HAI)
Number of subjects: 165
Study: 9459045

Group type: EXPERIMENTAL
Intervention: Omeprazole 20 mg enteric-coated tablet taken under fasting conditions
Number of subjects: 57

Group type: COMPARATOR
Intervention: Omeprazole 20 mg enteric-coated tablet taken before breakfast
Number of subjects: 57

Group type: COMPARATOR
Intervention: Omeprazole 20 mg enteric-coated tablet taken after breakfast
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Comparison of fasting and after breakfast regimens
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Comparison of fasting and before breakfast regimens
Number of subjects: 57
Study: 7932957

Group type: EXPERIMENTAL
Intervention: Mechanical heart valves
Number of subjects: 72

Group type: COMPARATOR
Intervention: Biological valves
Number of subjects: 72

Group type: COMPARATOR
Intervention: Mechanical valves
Number of subjects: 72
Study: 3070474

Group type: EXPERIMENTAL
Intervention: metaproterenol (1,300 micrograms) with Inspir‐Ease spacer
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: metaproterenol (1,300 micrograms) with Aerochamber spacer
Number of subjects: 13

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 13
Study: 31552590

Group type: EXPERIMENTAL
Intervention: CABG plus MVr
Number of subjects: 80

Group type: COMPARATOR
Intervention: CABG
Number of subjects: 80
Study: 29650371

Group type: EXPERIMENTAL
Intervention: Turo group (8-week Turo training program, 60-minute sessions twice a week)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Waiting-list control group (no additional treatment during the same period)
Number of subjects: 32
Study: 28329919

Group type: EXPERIMENTAL
Intervention: Gemcitabine plus cisplatin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Gemcitabine alone
Number of subjects: 0
Study: 26244978

Group type: EXPERIMENTAL
Intervention: Selective Cytopheretic Device (SCD) therapy
Number of subjects: 134

Group type: COMPARATOR
Intervention: Continuous renal replacement therapy (CRRT) alone
Number of subjects: 134
Study: 24257178

Group type: EXPERIMENTAL
Intervention: HUA group (76 cases)
Number of subjects: 157

Group type: COMPARATOR
Intervention: NUA group (81 cases)
Number of subjects: 157
Study: 21726427

Group type: EXPERIMENTAL
Intervention: PRP plus intravitreal ranibizumab (IVR)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Panretinal photocoagulation (PRP)
Number of subjects: 40
Study: 18362316

Group type: EXPERIMENTAL
Intervention: Mouthrinse containing 2% CPP-ACP and 450-ppm-F
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dentifrice containing 2% CPP-ACP
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dentifrice containing 2% CPP-ACP plus 1100 ppm F
Number of subjects: 0
Study: 16652079

Group type: EXPERIMENTAL
Intervention: Coblation-assisted partial turbinoplasty
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Microdebrider-assisted partial turbinoplasty
Number of subjects: 60
Study: 12785025

Group type: EXPERIMENTAL
Intervention: Crystacide applied around and on the ulcer for 10 days
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 10819810

Group type: EXPERIMENTAL
Intervention: Nonoxynol 9 suppository (150 mg, intravaginally for 3 consecutive nights)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Metronidazole (2 g, single oral dose)
Number of subjects: 46
Study: 8830962

Group type: EXPERIMENTAL
Intervention: Hydrocolloid dressing
Number of subjects: 0

Group type: COMPARATOR
Intervention: Knitted viscose dressing
Number of subjects: 0

Group type: COMPARATOR
Intervention: Gauze dressing
Number of subjects: 0
Study: 1447105

Group type: EXPERIMENTAL
Intervention: Cold exposure (10 degrees C)
Number of subjects: 19
Study: 6090368

Group type: EXPERIMENTAL
Intervention: Misonidazole (2.1-2.7 g/m2 per treatment day, given 4 hours before irradiation)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Irradiation alone
Number of subjects: 45
Study: 31283562

Group type: EXPERIMENTAL
Intervention: Recurrence Risk Score (RRS) for patients with symptomatic tumors, tumors >2 cm, Ki67 >3%, and lymph node (+) disease.
Number of subjects: 1006

Group type: EXPERIMENTAL
Intervention: Surveillance intervals proposed based on RRS.
Number of subjects: 1006
Study: 27633492

Group type: COMPARATOR
Intervention: Control condition (informed they would perform 12 MVCs)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Unknown condition (not informed of the number of MVCs to be completed, but stopped after 12)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Deception condition (instructed to complete 6 MVCs, however, after the sixth repetition performed another 6 MVCs)
Number of subjects: 14
Study: 25688059

Group type: EXPERIMENTAL
Intervention: CT plus Bev (7.5 mg/kg)
Number of subjects: 147

Group type: COMPARATOR
Intervention: CT alone
Number of subjects: 147

Group type: EXPERIMENTAL
Intervention: CT plus Bev
Number of subjects: 147
Study: 23724512

Group type: EXPERIMENTAL
Intervention: Transvaginal three-dimensional sonohysterography (3D SHSG)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Outpatient hysteroscopy
Number of subjects: 44
Study: 21036492

Group type: EXPERIMENTAL
Intervention: Gain-framed counseling and printed materials (n=810)
Number of subjects: 2032

Group type: COMPARATOR
Intervention: Standard-care counseling and printed materials (n=1222)
Number of subjects: 2032

Group type: COMPARATOR
Intervention: Standard-care messages (n=1222)
Number of subjects: 2032

Group type: EXPERIMENTAL
Intervention: Gain-framed messages (n=810)
Number of subjects: 2032
Study: 19236580

Group type: EXPERIMENTAL
Intervention: Duodenal acid perfusion (0.2 N, 5 mL min(‐1))
Number of subjects: 12

Group type: COMPARATOR
Intervention: Saline perfusion
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Duodenal acid perfusion
Number of subjects: 12
Study: 16251263

Group type: COMPARATOR
Intervention: Arm cycling
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tonic contraction
Number of subjects: 0
Study: 14639083

Group type: EXPERIMENTAL
Intervention: Self-reported symptoms (heaviness in past year, swelling now, numbness in past year)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Self-reported symptoms (heaviness in past year, swelling now)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Numbness in past year
Number of subjects: 80
Study: 10953178

Group type: COMPARATOR
Intervention: Control-stable
Number of subjects: 129

Group type: COMPARATOR
Intervention: Control-decliner
Number of subjects: 129

Group type: EXPERIMENTAL
Intervention: MCI-stable
Number of subjects: 129

Group type: EXPERIMENTAL
Intervention: MCI-decliner
Number of subjects: 129

Group type: EXPERIMENTAL
Intervention: AD
Number of subjects: 129
Study: 8610912

Group type: EXPERIMENTAL
Intervention: succinylcholine 1 mg/kg
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: rocuronium 0.6 mg/kg
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: mivacurium 0.2 mg/kg
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 100
Study: 1442316

Group type: EXPERIMENTAL
Intervention: CF neonatal screening
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 4060201

Group type: EXPERIMENTAL
Intervention: Prospidin combined with preoperative radiotherapy
Number of subjects: 27

Group type: COMPARATOR
Intervention: Preoperative radiotherapy alone
Number of subjects: 27
Study: 31703717

Group type: EXPERIMENTAL
Intervention: Abatacept
Number of subjects: 19
Study: 29508689

Group type: COMPARATOR
Intervention: Normal bread
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Bread treated with 0.8% ANPEP
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Bread treated with 1% ANPEP
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Low-protein bread made from biscuit flour
Number of subjects: 28

Group type: COMPARATOR
Intervention: Control bread
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: ANPEP treatment
Number of subjects: 28
Study: 26663152

Group type: EXPERIMENTAL
Intervention: Aleglitazar (150 µg once daily)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 25193295

Group type: EXPERIMENTAL
Intervention: LA roof ablation (LARA-1)
Number of subjects: 120

Group type: COMPARATOR
Intervention: PV isolation (LARA-2)
Number of subjects: 120
Study: 22472180

Group type: EXPERIMENTAL
Intervention: Endosonography followed by surgical staging if negative (n = 123)
Number of subjects: 241

Group type: COMPARATOR
Intervention: Surgical staging alone (n = 118)
Number of subjects: 241

Group type: EXPERIMENTAL
Intervention: Endosonography strategy
Number of subjects: 241

Group type: COMPARATOR
Intervention: Surgical staging alone
Number of subjects: 241